News about Biotechnology

Pandorum Partners with Nucelion Therapeutics to Manufacture Exosome-Based Ocular Therapy for APAC

Pandorum Technologies, a clinical-stage regenerative medicine company, has entered into a strategic manufacturing collaboration with Nucelion Therapeutics, the contract research, development and manufacturing organisation (CRDMO) arm of Bharat Biotech, to support the production of its exosome-based ocular disease therapy for the Asia-Pacific (APAC).

Biotechnology | 06/01/2026 | By Darshana |  269

BioAtla Advances Phase 3 Oz-V Programme with Manufacturing-Ready SPV Structure

BioAtla, Inc., a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapies for solid tumours, has entered into a special purpose vehicle (SPV) transaction with GATC Health Corp. to advance its lead asset, ozuriftamab vedotin (Oz-V), into a phase 3 clinical trial for second-line and later OPSCC.

Biotechnology | 04/01/2026 | By Darshana |  727

Mabwell Advances ADC Manufacturing Pipeline With NMPA-Backed Combination Trial Approval

Mabwell, an innovation-driven biopharmaceutical company with fully integrated capabilities spanning research and development, manufacturing, and commercialisation, announced that China’s National Medical Products Administration (NMPA) has approved the initiation of clinical trials for its independently developed B7-H3–targeting antibody–drug conjugate.

Biotechnology | 02/01/2026 | By Darshana |  336

Azenta Signs Definitive Agreement to Sell B Medical Systems to Thelema for USD 63 Million

Azenta, Inc., a leading provider of life sciences solutions worldwide, announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to Thelema S.À R.L., for a purchase price of USD 63 million. The transaction is expected to close on or before March 31, 2026.

Biotechnology | 30/12/2025 | By Darshana |  236

S&T Minister Dr Jitendra Singh inaugurates Biotechnology Research and Innovation Council (BRIC)

Union Minister of State (Independent Charge) for Science and Technology (S&T) Dr Jitendra Singh formally inaugurated the Biotechnology Research and Innovation Council (BRIC) Secretariat, on 29 December, by unveiling the inaugural curtain, marking the official opening of a new milestone in India’s biotechnology journey.

Biotechnology | 30/12/2025 | By Darshana |  154

GENESIS Pharma Secures Exclusive Rights to Commercialise Donidalorsen Across 14 CEE Markets

GENESIS Pharma, a regional biopharma company specialising in the commercialisation of innovative medicines in Central and Eastern Europe (CEE), has entered into an exclusive agreement with Otsuka Pharmaceutical Europe Ltd., the European arm of Otsuka Pharmaceutical Co., Ltd., for the distribution and commercialisation of donidalorsen.

Biotechnology | 16/12/2025 | By Darshana |  707

Vektor Medical Secures FDA Clearance for Next-Generation vMap Arrhythmia Mapping Technology

Vektor Medical, a San Diego–headquartered medical technology company focused on advancing arrhythmia diagnosis and treatment, has received US Food and Drug Administration 510(k) clearance for its next-generation vMap technology.

Biotechnology | 14/12/2025 | By Darshana |  436

Sentynl Appoints myTomorrows as Global Provider to Expand Managed Access Program

Sentynl Therapeutics, a biopharmaceutical company based in the USA and wholly owned by Zydus Lifesciences, has appointed myTomorrows as the global provider for its Managed Access Program (MAP).

Biotechnology | 11/12/2025 | By Darshana |  180

Zydus to Commercialise Keytruda Biosimilar FYB206 in US and Canada

Zydus Lifesciences has entered into an exclusive licensing agreement with Germany-based Formycon AG to commercialise FYB206, a biosimilar of the immunotherapy drug Keytruda (pembrolizumab), in the United States and Canada.

Biotechnology | 10/12/2025 | By Darshana |  298

Dr. Reddy's Signs USD 370 Million Licensing Deal for Eftilagimod Alfa

Dr. Reddy’s Laboratories has entered into an exclusive licensing agreement with Australian biotechnology company Immutep to commercialise its investigational immunotherapy, Eftilagimod Alfa (Efti), across markets outside North America, Europe, Japan and Greater China.

Biotechnology | 09/12/2025 | By Darshana |  195